{"id":23392,"date":"2026-06-16T05:22:56","date_gmt":"2026-06-16T05:22:56","guid":{"rendered":"https:\/\/engineerbabu.com\/blog\/?p=23392"},"modified":"2026-06-16T05:24:09","modified_gmt":"2026-06-16T05:24:09","slug":"pharmaceutical-software-development","status":"publish","type":"post","link":"https:\/\/engineerbabu.com\/blog\/pharmaceutical-software-development\/","title":{"rendered":"Pharmaceutical Software Development 2026 | EngineerBabu"},"content":{"rendered":"

An Indian pharmaceutical manufacturer, one of the thousands supplying generic drugs to US pharmacy chains received a chargeback notice from their US distributor in Q4 2025.<\/span><\/p>\n

The reason:<\/b> their serialization data was not DSCSA-compliant. Specifically, the EPCIS (<\/span>Electronic Product Code Information Services<\/span><\/a>) event data they were transmitting for their product shipments was in an older format that didn’t conform to the CBV (Core Business Vocabulary) 2.0 standard that the FDA’s 2025 enforcement framework required. The distributor couldn’t accept the product without valid EPCIS data. The shipment was held.<\/span><\/p>\n

The FDA’s Drug Supply Chain Security Act enforcement timeline is complete. Manufacturers crossed their May 27, 2025 deadline. Wholesale distributors crossed theirs on August 27, 2025. Large dispensers crossed November 27, 2025. The final deadline, small dispensers is November 27, 2026.<\/span><\/p>\n

For Indian generic manufacturers exporting to the US market, DSCSA compliance is not optional. It is the condition of entry.<\/span><\/p>\n

I co-founded <\/span>EngineerBabu<\/span><\/a> 14 years ago. The team built the Qubit pharma traceability platform, a track-and-trace serialization system for pharmaceutical manufacturers navigating DSCSA (US) and FMD (EU) compliance simultaneously.<\/span><\/p>\n

UUID-based serialization, EPCIS event generation, and integration with TraceLink and other US interoperability networks. That is the specific experience that makes this guide different from a generic software agency writing about pharma.<\/span><\/p>\n

The global pharmaceutical manufacturing software market reaches <\/span>$4.43 billion in 2026<\/span><\/a>, growing at 15.8% CAGR to $7.87 billion by 2030. India supplies 20% of global generics. Every Indian pharma exporter needs compliant software.<\/span><\/p>\n

Email <\/b>mayank@engineerbabu.com<\/b><\/a> for your pharma software build.<\/b><\/p>\n

\"\"
Only a Representation<\/figcaption><\/figure>\n

The Regulatory Landscape Every Indian Pharma Manufacturer Faces<\/b><\/h2>\n

1. DSCSA (United States – Drug Supply Chain Security Act)<\/b><\/h3>\n

Full enforcement active. Every prescription drug in the US supply chain must have:<\/span><\/p>\n